Abstract
Stroke is a leading cause of death and disability worldwide. However, after years of in-depth research, the pathophysiology of stroke is still not fully understood. Increasing evidence shows that matrix metalloproteinases (MMPs) and “a disintegrin and metalloproteinase” (ADAMs) participate in the neuro-inflammatory cascade that is triggered during stroke but also in recovery phases of the disease. This review covers the involvement of these proteins in brain injury following cerebral ischemia which has been widely studied in recent years, with efforts to modulate this group of proteins in neuroprotective therapies, together with their implication in neurorepair mechanisms. Moreover, the review also discusses the role of these proteins in specific forms of neurovascular disease, such as small vessel diseases and intracerebral hemorrhage. Finally, the potential use of MMPs and ADAMs as guiding biomarkers of brain injury and repair for decision-making in cases of stroke is also discussed.
Similar content being viewed by others
Abbreviations
- ADAM:
-
A disintegrin and metalloproteinase
- ADAMTS:
-
A disintegrin and metalloproteinase with thrombospondin motifs
- BBB:
-
Blood–brain barrier
- CAA:
-
Cerebral amyloid angiopathy
- COX:
-
Cyclooxygenase
- CSF:
-
Cerebrospinal fluid
- CSPGs:
-
Chondroitin sulfate-bearing proteoglycans
- CT:
-
Computed tomography
- EPCs:
-
Endothelial progenitor cells
- ICH:
-
Intracerebral hemorrhage
- MMP:
-
Matrix metalloproteinase
- MT:
-
Mechanical thrombectomy
- OGD:
-
Oxygen–glucose–deprivation
- PHE:
-
Perihematomal edema
- PNN:
-
Perineuronal net
- SAH:
-
Subarachnoid hemorrhage
- SIVD:
-
Subcortical ischemic vascular disease or vascular cognitive impairment
- SVD:
-
Small vessel diseases
- TACE:
-
Tumor necrosis factor alpha converting enzyme
- TIMP:
-
Tissue inhibitor of MMPs
- TNFa:
-
Tumor necrosis factor alpha
- tPA:
-
Tissue-plasminogen activator
- VWF:
-
Von Willebrand factor
- WMH:
-
White matter hyperintensity
References
Benjamin EJ, Virani SS, Callaway CW et al (2018) heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation 137:e67–e492. https://doi.org/10.1161/CIR.0000000000000558
Hui C, Tadi P, Patti L (2019) Ischemic stroke. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)
Lo EH, Dalkara T, Moskowitz MA (2003) Neurological diseases: mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399–414. https://doi.org/10.1038/nrn1106
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren NTD (2005) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. Clin Trials 359:1317–1329
Urra X, Abilleira S, Dorado L et al (2015) Mechanical thrombectomy in and outside the REVASCAT trial: insights from a concurrent population-based stroke registry. Stroke 46:3437–3442. https://doi.org/10.1161/STROKEAHA.115.011050
Nogueira RG, Jadhav AP, Haussen DC et al (2017) Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378:11–21. https://doi.org/10.1056/NEJMoa1706442
Mac Grory B, Yaghi S (2018) Updates in stroke treatment. R I Med J 101:30–33
Bernhardt J, Zorowitz RD, Becker KJ et al (2018) Advances in stroke 2017. Stroke 49:e174–e199. https://doi.org/10.1161/STROKEAHA.118.021380
Vidale S, Consoli A, Arnaboldi M, Consoli D (2017) Postischemic inflammation in acute stroke. J Clin Neurol 13:1–9. https://doi.org/10.3988/jcn.2017.13.1.1
Ramiro L, Simats A, García-Berrocoso T, Montaner J (2018) Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Ther Adv Neurol Disord. https://doi.org/10.1177/1756286418789340
Asahi M, Wang X, Mori T et al (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724–7732. https://doi.org/10.1523/JNEUROSCI.21-19-07724.2001
Rosenberg GA, Estrada EY, Dencoff JE, Hsu CY (1998) Matrix metalloproteinases and TIMPs are associated with blood–brain barrier opening after reperfusion in rat brain editorial comment. Stroke 29:2189–2195. https://doi.org/10.1161/01.STR.29.10.2189
Romanic AM, White RF, Arleth AJ et al (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020–1030. https://doi.org/10.1161/01.STR.29.5.1020
Yang Y, Estrada EY, Thompson JF et al (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697–709. https://doi.org/10.1038/sj.jcbfm.9600375
Asahi M, Asahi K, Jung JC et al (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681–1689. https://doi.org/10.1097/00004647-200012000-00007
Zhao BQ, Wang S, Kim HY et al (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12:441–445. https://doi.org/10.1038/nm1387
Heo JH, Lucero J, Abumiya T et al (1999) Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624–633. https://doi.org/10.1097/00004647-199906000-00005
Montaner J, Molina CA, Monasterio J et al (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598–603. https://doi.org/10.1161/01.CIR.0000046451.38849.90
Wang X, Lee SR, Arai K et al (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313–1317. https://doi.org/10.1038/nm926
Sumii T, Lo EH (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831–836. https://doi.org/10.1161/hs0302.104542
Rosenberg GA, Cunningham LA, Wallace J et al (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893:104–112. https://doi.org/10.1016/S0006-8993(00)03294-7
Gasche Y, Fujimura M, Morita-Fujimura Y et al (1999) Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood–brain barrier dysfunction. J Cereb Blood Flow Metab 19:1020–1028. https://doi.org/10.1097/00004647-199909000-00010
Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PHPT (2005) Leukocyte-derived matrix metalloproteinase-9 mediates blood–brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. AJP Hear Circ Physiol 289:H558–H568. https://doi.org/10.1152/ajpheart.01275.2004
Gu Z, Cui J, Brown S et al (2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25:6401–6408. https://doi.org/10.1523/JNEUROSCI.1563-05.2005
Gasche Y, Copin JC, Sugawara T et al (2001) Matrix metalloproteinase inhibition prevents oxidative stress-associated blood–brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393–1400. https://doi.org/10.1097/00004647-200112000-00003
Lapchak PA, Chapman DF, Zivin JA (2000) Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31:3034–3040. https://doi.org/10.1161/01.STR.31.12.3034
Montaner J, Alvarez-Sabín J, Molina C et al (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759–1766. https://doi.org/10.1161/01.STR.32.8.1759
Rosell A, Ortega-Aznar A, Alvarez-Sabín J et al (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37:1399–1406. https://doi.org/10.1161/01.STR.0000223001.06264.af
Castellanos M, Leira R, Serena J et al (2003) Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34:40–45. https://doi.org/10.1161/01.STR.0000046764.57344.31
Rosell A, Cuadrado E, Ortega-Aznar A et al (2008) MMP-9-positive neutrophil infiltration is associated to blood–brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39:1121–1126. https://doi.org/10.1161/STROKEAHA.107.500868
Fujimura M, Gasche Y, Morita-Fujimura Y et al (1999) Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842:92–100. https://doi.org/10.1016/S0006-8993(99)01843-0
Montaner J, Alvarez-Sabín J, Molina CA et al (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762–2767. https://doi.org/10.1161/hs1201.99512
Clark AW, Krekoski CA, Bou SS et al (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53–56. https://doi.org/10.1016/S0304-3940(97)00859-8
Rosenberg GA, Kornfeld M, Estrada E et al (1992) TIMP-2 reduces proteolytic opening of blood–brain barrier by type IV collagenase. Brain Res 576:203–207. https://doi.org/10.1016/0006-8993(92)90681-X
Anthony DC, Ferguson B, Matyzak MK et al (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406–415. https://doi.org/10.1111/j.1365-2990.1997.tb01315.x
Pfefferkorn T, Rosenberg GA (2003) Closure of the blood–brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34:2025–2030. https://doi.org/10.1161/01.STR.0000083051.93319.28
Lee SR, Kim HY, Rogowska J, Zhao BQ, Bhide P, Le Parent JM (2006) Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 26:3491–3495. https://doi.org/10.1523/JNEUROSCI.4085-05.2006
Wang J, Tsirka SE (2005) Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128:1622–1633. https://doi.org/10.1093/brain/awh489
Lee SR, Tsuji K, LE Lee SR (2004) Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24:671–678. https://doi.org/10.1523/JNEUROSCI.4243-03.2004
Horstmann S, Kalb P, Koziol J et al (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34:2165–2170. https://doi.org/10.1161/01.STR.0000088062.86084.F2
Park K-P, Rosell A, Foerch C et al (2009) Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 40:2836–2842. https://doi.org/10.1161/STROKEAHA.109.554824
Cuadrado E, Rosell A, Penalba A et al (2009) Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res 8:3191–3197
Lo EH, Wang X, Cuzner ML (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 69:1–9. https://doi.org/10.1002/jnr.10270
Planas AM, Solé S, Justicia C (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8:834–846. https://doi.org/10.1006/nbdi.2001.0435
Solé S, Petegnief V, Gorina R et al (2004) Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol 63:338–349. https://doi.org/10.1093/jnen/63.4.338
Cuadrado E, Rosell A, Borrell-Pagès M et al (2009) Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J Cereb Blood Flow Metab 29:398–410. https://doi.org/10.1038/jcbfm.2008.130
Gurney KJ, Estrada EY, Rosenberg GA (2006) Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23:87–96. https://doi.org/10.1016/j.nbd.2006.02.006
Chelluboina B, Klopfenstein JD, Pinson DM et al (2015) Matrix metalloproteinase-12 induces blood–brain barrier damage after focal cerebral ischemia. Stroke 46:3523–3531. https://doi.org/10.1161/STROKEAHA.115.011031
Hurtado O, Cárdenas A, Lizasoain I et al (2001) Up-regulation of TNF-α convertase (TACE/ADAM17) after oxygen–glucose deprivation in rat forebrain slices. Neuropharmacology 40:1094–1102. https://doi.org/10.1016/S0028-3908(01)00035-1
Marshall AJ, Rattray M, Vaughan PFT (2006) Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative α-secretases, ADAM10 and TACE, without altering their mRNA levels. Brain Res 1099:18–24. https://doi.org/10.1016/j.brainres.2006.05.008
Auerbach ID, Vinters HV (2006) Effects of anoxia and hypoxia on amyloid precursor protein processing in cerebral microvascular smooth muscle cells. J Neuropathol Exp Neurol 65:610–620
Cross AK, Haddock G, Stock CJ et al (2006) ADAMTS-1 and -4 are up-regulated following transient middle cerebral artery occlusion in the rat and their expression is modulated by TNF in cultured astrocytes. Brain Res 1088:19–30. https://doi.org/10.1016/j.brainres.2006.02.136
Reid MJ, Cross AK, Haddock G et al (2009) ADAMTS-9 expression is up-regulated following transient middle cerebral artery occlusion (tMCAo) in the rat. Neurosci Lett 452:252–257. https://doi.org/10.1016/j.neulet.2009.01.058
Lemarchant S, Dunghana H, Pomeshchik Y et al (2016) Anti-inflammatory effects of ADAMTS-4 in a mouse model of ischemic stroke. Glia 64:1492–1507. https://doi.org/10.1002/glia.23017
Tejima E, Guo S, Murata Y et al (2009) Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma 26:1935–1941. https://doi.org/10.1089/neu.2009.0959
Lu A, Suofu Y, Guan F, Broderick JP, Wagner KRCJ (2013) Matrix metalloproteinase-2 deletions protect against hemorrhagic transformation after 1 h of cerebral ischemia and 23 h of reperfusion. Neuroscience 253:361–367. https://doi.org/10.1088/1367-2630/15/1/015008.Fluid
Jiang X, Namura S, Nagata I (2001) Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 305:41–44
Lovering F, Zhang Y (2005) Therapeutic potential of TACE inhibitors in stroke. Curr Drug Target CNS Neurol Disord 4:161–168. https://doi.org/10.2174/1568007053544147
Cui J, Chen S, Zhang C et al (2012) Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener 7:21. https://doi.org/10.1186/1750-1326-7-21
Ranasinghe HS, Scheepens A, Sirimanne E et al (2012) Inhibition of MMP-9 activity following hypoxic ischemia in the developing brain using a highly specific inhibitor. Dev Neurosci 34:417–427. https://doi.org/10.1159/000343257
Koistinaho M, Malm TM, Kettunen MI et al (2005) Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 25:460–467. https://doi.org/10.1038/sj.jcbfm.9600040
Machado LS, Sazonova I, Kozak A et al (2009) Minocycline and tissue plasminogen activator for stroke: assessment of interaction potential. Stroke 40:3028–3033. https://doi.org/10.1111/j.1365-2125.2008.03198.x
Machado LS, Kozak A, Ergul A et al (2006) Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci 7:1–7. https://doi.org/10.1186/1471-2202-7-56
Zhang L, Chopp M, Jia L et al (2009) Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 29:1816–1824. https://doi.org/10.1038/jcbfm.2009.105
Jang JW, Lee JK, Lee MC et al (2012) Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model. J Neurol Sci 323:221–227. https://doi.org/10.1016/j.jns.2012.09.021
Tanaka H, Takai S, Jin D et al (2007) Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 30:469–475. https://doi.org/10.1291/hypres.30.469
Okamoto K, Takai S, Sasaki S, Miyazaki M (2002) Trandolapril reduces infarction area after middle cerebral artery occlusion in rats. Hypertens Res 25:583–588. https://doi.org/10.1291/hypres.25.583
Candelario-Jalil E, Taheri S, Yang Y et al (2007) Cyclooxygenase inhibition limits blood–brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 323:488–498. https://doi.org/10.1124/jpet.107.127035
Hamann GF, Burggraf D, Martens HK et al (2004) Mild to moderate hypothermia prevents microvascular basal lamina antigen loss in experimental focal cerebral ischemia. Stroke 35:764–769. https://doi.org/10.1161/01.STR.0000116866.60794.21
Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, Duan JJ, Decicco CPLR (2004) Inhibition of tumor necrosis factor-α-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol 65:890–896. https://doi.org/10.1124/mol.65.4.890
Hurtado O, Lizasoain I, Fernández-Tomé P et al (2002) TACE/ADAM17-TNF-alpha pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate. J Cereb Blood Flow Metab 22:576–585. https://doi.org/10.1097/00004647-200205000-00009
Vidal PM, Lemmens E, Avila A et al (2013) ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice. Cell Death Dis 4:e954. https://doi.org/10.1038/cddis.2013.466
Cárdenas A, Moro MA, Leza JC et al (2002) Upregulation of TACE/ADAM17 after ischemic preconditioning is involved in brain tolerance. J Cereb Blood Flow Metab 22:1297–1302. https://doi.org/10.1097/01.WCB.0000033968.83623.D0
Wang Y, Herrera AH, Li Y et al (2009) Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol 182:2449–2457. https://doi.org/10.4049/jimmunol.0802770
Venturi GM, Tu L, Kadono T et al (2003) Leukocyte migration is regulated by L-selectin endoproteolytic release. Immunity 19:713–724. https://doi.org/10.1016/s1074-7613(03)00295-4
Schaff U, Mattila PE, Simon SI, Walcheck B (2007) Neutrophil adhesion to E-selectin under shear promotes the redistribution and co-clustering of ADAM17 and its proteolytic substrate L-selectin. J Leukoc Biol 83:99–105. https://doi.org/10.1189/jlb.0507304
Garton KJ, Gough PJ, Blobel CP et al (2001) Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276:37993–38001. https://doi.org/10.1074/jbc.M106434200
Koenen RR, Pruessmeyer J, Soehnlein O et al (2009) Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood 113:4799–4809. https://doi.org/10.1182/blood-2008-04-152330
Zhao BQ, Chauhan AKK, Canault M et al (2009) von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 114:3329–3334. https://doi.org/10.1182/blood-2009-03-213264
Fan M, Xu H, Wang L et al (2016) Tissue plasminogen activator neurotoxicity is neutralized by recombinant ADAMTS 13. Sci Rep 6:1–11. https://doi.org/10.1038/srep25971
Khan M, Motto D, Lentz S, Chauhan A (2012) ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost 10:1665–1671. https://doi.org/10.1111/j.1538-7836.2012.04822.x.ADAMTS13
Fujioka M, Nakano T, Hayakawa K et al (2012) ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury. Neurol Sci 33:1107–1115. https://doi.org/10.1007/s10072-011-0913-9
Chauhan AK, Kisucka J, Brill A et al (2008) ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 205:2065–2074. https://doi.org/10.1084/jem.20080130
De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C (2013) von Willebrand factor: an emerging target in stroke therapy. Stroke 6:599–606. https://doi.org/10.1021/nn300902w.Release
Pendu R, Terraube V, Christophe OD et al (2006) P-selectin glycoprotein ligand 1 and B2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 108:3746–3752. https://doi.org/10.1182/blood-2006-03-010322
Bernardo A, Ball C, Nolasco L et al (2005) Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 3:562–570. https://doi.org/10.1111/j.1538-7836.2005.01122.x
Tsuji K, Aoki T, Tejima E et al (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36:1954–1959. https://doi.org/10.1161/01.STR.0000177517.01203.eb
Hu K, Yang J, Tanaka S et al (2006) Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 281:2120–2127. https://doi.org/10.1074/jbc.M504988200
Suzuki Y (2010) Role of tissue-type plasminogen activator in ischemic stroke. J Pharmacol Sci 113:203–207. https://doi.org/10.1254/jphs.10R01CP
Cuadrado E, Ortega L, Hernandez-Guillamon M et al (2008) Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 84:207–214. https://doi.org/10.1189/jlb.0907606
Mishiro K, Ishiguro M, Suzuki Y et al (2012) A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice. Neuroscience 205:39–48. https://doi.org/10.1016/j.neuroscience.2011.12.042
Murata Y, Rosell A, Scannevin RH et al (2008) Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39:3372–3377. https://doi.org/10.1161/STROKEAHA.108.514026
Copin J, Merlani P, Sugawara T (2008) Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 213:196–201. https://doi.org/10.1016/j.expneurol.2008.05.022
Fagan SC, Waller JL, Nichols FT et al (2010) Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 41:2283–2287. https://doi.org/10.1161/STROKEAHA.110.582601
Switzer JA, Hess DC, Ergul A et al (2011) Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 42:2633–2635. https://doi.org/10.1161/STROKEAHA.111.618215
Wang L, Fan W, Cai P et al (2013) Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol 73:189–198. https://doi.org/10.1002/ana.23762
Denorme F, Langhauser F, Desender L et al (2016) ADAMTS13- mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice. Blood 127:2337–2345. https://doi.org/10.1182/blood-2015-08-662650.The
Li Z, Nardi MA, Li YS et al (2009) C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates, and protects against carotid artery occlusion and cerebral stroke. Blood 113:6051–6060. https://doi.org/10.1182/blood-2008-07-170571
Rosell A, Lo EH (2008) Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 8:82–89. https://doi.org/10.1016/j.coph.2007.12.001
Lo EH (2008) A new penumbra: transitioning from injury into repair after stroke. Nat Med 14:497
Carmichael T (2006) Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol. https://doi.org/10.4261/1305-3825.DIR.3079-09.1
Sood RR, Taheri S, Candelario-Jalil E et al (2008) Early beneficial effect of matrix metalloproteinase inhibition on blood–brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab 28:431–438. https://doi.org/10.1038/sj.jcbfm.9600534
Wójcik-Stanaszek L, Sypecka J, Szymczak P et al (2011) The potential role of metalloproteinases in neurogenesis in the gerbil hippocampus following global forebrain ischemia. PLoS One 6:e22465. https://doi.org/10.1371/journal.pone.0022465
Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, LeTourneau Y, Wang YCM (2006) Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 26:5996–6003. https://doi.org/10.1523/JNEUROSCI.5380-05.2006
Barkho BZ, Munoz AE, Li X, Li L, La Cunningham ZX (2008) Endogenous matrix metalloproteinase (MMP)-3 and MMP-9 promote the differentiation and migration of adult neural progenitor cells in response to chemokines. Stem Cells 12:3139–3149
Ma F, Martínez-San Segundo P, Barceló V et al (2016) Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2016.03.016
Ohab JJ, Fleming S, Blesch A, Carmichael ST (2006) A neurovascular niche for neurogenesis after stroke. J Neurosci 26:13007–13016. https://doi.org/10.1523/JNEUROSCI.4323-06.2006
Ould-Yahoui A, Sbai O, Baranger K et al (2013) Role of matrix metalloproteinases in migration and neurotrophic properties of nasal olfactory stem and ensheathing cells. Cell Transplant 22:993–1010. https://doi.org/10.3727/096368912X657468
Esquiva G, Grayston A, Rosell A (2018) Revascularization and endothelial progenitor cells in stroke. Am J Physiol Cell Physiol 315:C664–C674. https://doi.org/10.1152/ajpcell.00200.2018
Huang PH, Chen YH, Wang CH, Chen JS, Tsai HY, Lin FY, Lo WY, Wu TC, Sata M, Chen JWLS (2009) Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 8:1179–1184
Morancho A, Hernández-Guillamon M, Boada C et al (2013) Cerebral ischaemia and matrix metalloproteinase-9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. J Cell Mol Med 17:1543–1553. https://doi.org/10.1111/jcmm.12116
Johnson C, Sung HJ, Lessner SM et al (2004) Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 94:262–268. https://doi.org/10.1161/01.RES.0000111527.42357.62
Rosell A, Morancho A, Navarro-Sobrino M et al (2013) Factors secreted by endothelial progenitor cells enhance neurorepair responses after cerebral ischemia in mice. PLoS One. https://doi.org/10.1371/journal.pone.0073244
Moubarik C, Guillet B, Youssef B et al (2011) Transplanted late outgrowth endothelial progenitor cells as cell therapy product for stroke. Stem Cell Rev Rep. https://doi.org/10.1007/s12015-010-9157-y
Morancho A, Ma F, Barceló V et al (2015) Impaired vascular remodeling after endothelial progenitor cell transplantation in MMP9-deficient mice suffering cortical cerebral ischemia. J Cereb Blood Flow Metab. https://doi.org/10.1038/jcbfm.2015.180
Gottschall PE, Howell MD (2015) ADAMTS expression and function in central nervous system injury and disorders. Matrix Biol 44–46:70–76. https://doi.org/10.1016/j.matbio.2015.01.014
Lemarchant S, Pruvost M, Montaner J et al (2013) ADAMTS proteoglycanases in the physiological and pathological central nervous system. J Neuroinflamm 10:133. https://doi.org/10.1186/1742-2094-10-133
Quraishe S, Forbes LHAM (2018) The extracellular environment of the CNS: influence on plasticity, sprouting, and axonal regeneration after spinal cord injury. Neural Plast 2018:2952386
Yuan W, Matthews RT, Sandy JD, Gottschall PE (2002) Association between protease-specific proteolytic cleavage of brevican and synaptic loss in the dentate gyrus of kainate-treated rats. Neuroscience. https://doi.org/10.1016/S0306-4522(02)00347-0
Hamel MG, Ajmo JM, Leonardo CC et al (2008) Multimodal signaling by the ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) promotes neurite extension. Exp Neurol 210:428–440. https://doi.org/10.1016/j.expneurol.2007.11.014
Wardlaw JM, Smith C, Dichgans M (2013) Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 12:483–497. https://doi.org/10.1016/S1474-4422(13)70060-7
Candelario-Jalil E, Thompson J, Taheri S et al (2011) Matrix metalloproteinases are associated with increased blood–brain barrier opening in vascular cognitive impairment. Stroke 42:1345–1350. https://doi.org/10.1161/STROKEAHA.110.600825
Bjerke M, Jonsson M, Nordlund A et al (2014) Cerebrovascular biomarker profile is related to white matter disease and ventricular dilation in a LADIS substudy. Dement Geriatr Cogn Dis Extra 4:385–394. https://doi.org/10.1159/000366119
Barry Erhardt E, Pesko JC, Prestopnik J, Thompson J, Caprihan A, Rosenberg GA (2018) Biomarkers identify the Binswanger type of vascular cognitive impairment. J Cereb Blood Flow Metab 7:271678X18762655. https://doi.org/10.1177/0271678X18762655
Rosenberg GA (2016) Matrix metalloproteinase-mediated neuroinflammation in vascular cognitive impairment of the Binswanger type. Cell Mol Neurobiol 36:195–202. https://doi.org/10.1007/s10571-015-0277-4
Vilar-Bergua A, Riba-Llena I, Nafría C et al (2016) Blood and CSF biomarkers in brain subcortical ischemic vascular disease: involved pathways and clinical applicability. J Cereb Blood Flow Metab 36:55–71. https://doi.org/10.1038/jcbfm.2015.68
Arba F, Piccardi B, Palumbo V et al (2018) Small vessel disease is associated with tissue inhibitor of matrix metalloproteinase-4 after ischaemic stroke. Transl Stroke Res 10:44
Ketsawatsomkron P, Keen HL, Davis DR et al (2016) Protective role for tissue inhibitor of metalloproteinase-4, a novel peroxisome proliferator-activated receptor-γ target gene, in smooth muscle in deoxycorticosterone acetate-salt hypertension. Hypertension 67:214–222. https://doi.org/10.1161/HYPERTENSIONAHA.115.06391
Radomski A, Jurasz P, Sanders EJ et al (2002) Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol 137:1330–1338. https://doi.org/10.1038/sj.bjp.0704936
Yang YRG (2015) Matrix metalloproteinases as therapeutic targets for stroke. Brain Res 1623:30–38
Walz WCF (2017) Neutrophil infiltration and matrix metalloproteinase-9 in lacunar infarction. Neurochem Res 42:2560–2565
Kawano T, Miyashita K, Takeuchi M et al (2018) Blood biomarkers associated with neurological deterioration in patients with acute penetrating artery territory infarction: a multicenter prospective observational study. Int J Stroke 13:207–216. https://doi.org/10.1177/1747493016677982
Florczak-Rzepka M, Grond-Ginsbach C, Montaner J, Steiner T (2012) Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: an update. Cerebrovasc Dis 34:249–262. https://doi.org/10.1159/000341686
Abilleira S, Montaner J, Molina CA, Monasterio J et al (2003) Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 99:65–70. https://doi.org/10.3171/jns.2003.99.1.0065
Silva Y, Leira R, Tejada J et al (2005) Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 36:86–91. https://doi.org/10.1161/01.STR.0000149615.51204.0b
Alvarez-Sabín J, Delgado P, Abilleira S et al (2004) Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 35:1316–1322. https://doi.org/10.1161/01.STR.0000126827.69286.90
Li N, Liu YF, Ma L et al (2013) Association of molecular markers with perihematomal edema and clinical outcome in intracerebral hemorrhage. Stroke 44:658–663. https://doi.org/10.1161/STROKEAHA.112.673590
Howe MD, Zhu L, Sansing LH et al (2018) Serum markers of blood–brain barrier remodeling and fibrosis as predictors of etiology and clinicoradiologic outcome in intracerebral hemorrhage. Front Neurol 9:746. https://doi.org/10.3389/fneur.2018.00746
Rosenberg GA, Navratil M, Aschoff A, Schwab S (1997) Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 48:921–926. https://doi.org/10.1212/wnl.54.2.354
Power C, Henry S, Del Bigio MR et al (2003) Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. https://doi.org/10.1002/ana.10553
Xue M, Fan Y, Liu S et al (2009) Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage. Brain 123:26–36. https://doi.org/10.1093/brain/awn215
Tejima E, Zhao BQ, Tsuji K et al (2007) Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab 27:460–468. https://doi.org/10.1038/sj.jcbfm.9600354
Reuter B, Bugert P, Stroick M et al (2009) TIMP-2 gene polymorphism is associated with intracerebral hemorrhage. Cerebrovasc Dis 28:558–563. https://doi.org/10.1159/000247599
Wang HX, Yang QD, Liu BQ et al (2014) TIMP-1 polymorphisms in a Chinese Han population with intracerebral hemorrhage. Int J Neurosci 124:61–67. https://doi.org/10.3109/00207454.2013.823604
Chen YC, Ho WM, Lee YS et al (2015) Polymorphisms in the promoters of the MMP-2 and TIMP-2 genes are associated with spontaneous deep intracerebral hemorrhage in the Taiwan population. PLoS One 10:e0142482. https://doi.org/10.1371/journal.pone.0142482
Ho W-M, Chen C-M, Lee Y-S et al (2015) Association of MMP-9 haplotypes and TIMP-1 polymorphism with spontaneous deep intracerebral hemorrhage in the Taiwan population. PLoS One 10:e0125397. https://doi.org/10.1371/journal.pone.0125397
Lee JM, Yin KJ, Hsin I et al (2003) Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 54:379–382. https://doi.org/10.1002/ana.10671
Hernandez-Guillamon M, Mawhirt S, Fossati S et al (2010) Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-βE22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. J Biol Chem 285:27144–27158. https://doi.org/10.1074/jbc.M110.135228
Hernandez-Guillamon M, Martinez-Saez E, Delgado P et al (2012) MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol. https://doi.org/10.1111/j.1750-3639.2011.00512.x
Zhao L, Arbel-Ornath M, Wang X et al (2015) Matrix metalloproteinase 9-mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy. Neurobiol Aging. https://doi.org/10.1016/j.neurobiolaging.2015.07.016
Wells JE, Biernaskie J, Szymanska A, Larsen PH, Yong VWCD (2005) Matrix metalloproteinase (MMP)-12 expression has a negative impact on sensorimotor function following intracerebral haemorrhage in mice. Eur J Neurosci 21:187–196
Tang J, Liu J, Zhou C et al (2004) MMP-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cereb Blood Flow Metab. https://doi.org/10.1097/01.WCB.0000135593.05952.DE
Grossetete M, Rosenberg GA (2008) Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J Cereb Blood Flow Metab 28:752–763. https://doi.org/10.1038/sj.jcbfm.9600572
Parks WC, Parks WC, Wilson CL et al (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617–629. https://doi.org/10.1038/nri1418
Kim SC, Singh M, Huang J et al (1997) Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 41:642–666. https://doi.org/10.1097/00006123-199709000-00027
Bruno G, Todor R, Lewis I, Chyatte D (1998) Vascular extracellular matrix remodeling in cerebral aneurysms. J Neurosurg 89:431–440. https://doi.org/10.3171/jns.1998.89.3.0431
Fischer M, Dietmann A, Beer R et al (2013) Differential regulation of matrix-metalloproteinases and their tissue inhibitors in patients with aneurysmal subarachnoid hemorrhage. PLoS One 8:e59952. https://doi.org/10.1371/journal.pone.0059952
Wang LGZ (2018) Expression of MMP-9 and IL-6 in patients with subarachnoid hemorrhage and the clinical significance. Exp Ther Med 15:1510–1514
Söderholm M, Nordin Fredrikson G, Nilsson JEG (2018) High serum level of matrix metalloproteinase-7 is associated with increased risk of spontaneous subarachnoid hemorrhage. Stroke 49:1626–1631
Kumar M, Cao W, McDaniel JK, Pham HP, Raju D, Nawalinski K, Frangos S, Kung D, Zager E, Kasner SE, Levine JMZX (2017) Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage. Thromb Haemost 117:691–699
Cai P, Luo H, Xu H et al (2015) Recombinant ADAMTS 13 attenuates brain injury after intracerebral hemorrhage. Stroke 46:2647–2653. https://doi.org/10.1161/STROKEAHA.115.009526
Rosell A, Alvarez-Sabín J, Arenillas JF et al (2005) A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415–1420. https://doi.org/10.1161/01.STR.0000170641.01047.cc
Ning M, Furie KL, Koroshetz WJ et al (2006) Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 66:1550–1555. https://doi.org/10.1212/01.wnl.0000216133.98416.b4
Rodríguez JA, Sobrino T, Orbe J et al (2013) proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke. J Thromb Haemost 11:1464–1473. https://doi.org/10.1111/jth.12312
Worthmann H, Tryc AB, Goldbecker A et al (2010) The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 30:85–92. https://doi.org/10.1159/000314624
McCabe DJH, Murphy SJX, Starke R et al (2015) Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci 348:35–40. https://doi.org/10.1016/j.jns.2014.10.035
Qu L, Jiang M, Qiu W et al (2016) Assessment of the diagnostic value of plasma levels, activities, and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction. Clin Appl Thromb 22:252–259. https://doi.org/10.1177/1076029615583347
Ling JY, Shen L, Liu Q et al (2013) Changes in platelet GPIbα and ADAM17 during the acute stage of atherosclerotic ischemic stroke among Chinese. J Huazhong Univ Sci Technol Med Sci 33:438–442. https://doi.org/10.1007/s11596-013-1138-3
Peeters SA, Engelen L, Buijs J et al (2017) Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol 16:55. https://doi.org/10.1186/s12933-017-0539-1
Tayebjee MH, Nadar S, Blann AD et al (2004) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17:764–769. https://doi.org/10.1016/j.amjhyper.2004.05.019
Eldrup N, Grønholdt MLM, Sillesen H, Nordestgaard BG (2006) Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.105.593483
Zielinska-Turek J, Dorobek M, Turek GB-KM (2018) MMP-9 and/or TIMP as predictors of ischaemic stroke in patients with symptomatic and asymptomatic atherosclerotic stenosis of carotid artery treated by stenting or endarterectomy—a review. Neurol Neurochir Pol 52:555–561
Abbas A, Aukrust P, Russell D et al (2014) Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One. https://doi.org/10.1371/journal.pone.0084935
Peeters W, Moll FL, Vink A et al (2011) Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J 32:2314–2325. https://doi.org/10.1093/eurheartj/ehq517
Tsioufis C, Konstantinidis D, Nikolakopoulos E, Vemou E, Kalos T, Georgiopoulos G, Vogiatzakis N, Ifantis A, Konstantinou K, Gennimata V, Tousoulis D (2019) Biomarkers of atrial fibrillation in hypertension. Curr Med Chem 26(5):888–897. https://doi.org/10.2174/0929867324666171006155516
Sonneveld MAH, De Maat MPM, Portegies MLP et al (2015) Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. https://doi.org/10.1182/blood-2015-05-643338
Kaikita K, Soejima K, Matsukawa M et al (2006) Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 4:2490–2493. https://doi.org/10.1111/j.1538-7836.2006.02161.x
Stefano R, Massimiliano C, Marina C et al (2015) A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis. Atherosclerosis 239:459–464. https://doi.org/10.1016/j.atherosclerosis.2015.01.029
Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernández E, Pascual J, Soler MJ (2018) Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfy240
Montaner J, Mendioroz M, Ribó M et al (2011) A panel of biomarkers including caspase-3 and d-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. J Intern Med 270:166–174. https://doi.org/10.1111/j.1365-2796.2010.02329.x
Bustamante A, López-Cancio E, Pich S et al (2017) Blood biomarkers for the early diagnosis of stroke: the stroke-chip study. Stroke 48:2419–2425. https://doi.org/10.1161/STROKEAHA.117.017076
Lind L, Siegbahn A, Lindahl B et al (2015) Discovery of new risk markers for ischemic stroke using a novel targeted proteomics chip. Stroke 46:3340–3347. https://doi.org/10.1161/STROKEAHA.115.010829
Sharma R, Macy S, Richardson K et al (2014) A blood-based biomarker panel to detect acute stroke. J Stroke Cerebrovasc Dis 23:910–918. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.034
Wang L, Wei C, Deng L et al (2018) The accuracy of serum matrix metalloproteinase-9 for predicting hemorrhagic transformation after acute ischemic stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 27:1653–1665. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.023
Serena J, Blanco M, Castellanos M et al (2005) The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 36:1921–1926. https://doi.org/10.1161/01.STR.0000177870.14967.94
Piccardi B, Palumbo V, Nesi M et al (2015) Unbalanced metalloproteinase-9 and tissue inhibitors of metalloproteinases ratios predict hemorrhagic transformation of lesion in ischemic stroke patients treated with thrombolysis: results from the MAGIC study. Front Neurol 6:121. https://doi.org/10.3389/fneur.2015.00121
Zhong C, Yang J, Xu T et al (2017) Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. Neurology 89:805–812. https://doi.org/10.1212/WNL.0000000000004257
Gori AM, Giusti B, Piccardi B et al (2017) Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis. J Cereb Blood Flow Metab 37:3253–3261. https://doi.org/10.1177/0271678X17695572
Schuppner R, Dirks M, Grosse GM et al (2018) ADAMTS-13 activity predicts outcome in acute ischaemic stroke patients undergoing endovascular treatment. Thromb Haemost 118:758–767. https://doi.org/10.1055/s-0038-1637732
Prochazka V, Jonszta T, Czerny D, Krajca J, Roubec M, Macak J, Kovar P, Kovarova P, Pulcer M, Zoubkova R, Lochman I, Svachova V, Pavliska L, Vrtkova A, Kasprak D, Gumulec JWJ (2018) The role of von Willebrand factor, ADAMTS13, and cerebral artery thrombus composition in patient outcome following mechanical thrombectomy for acute ischemic stroke. Med Sci Monit 24:3929–3945
Sharma R, Gowda H, Chavan S et al (2015) Proteomic signature of endothelial dysfunction identified in the serum of acute ischemic stroke patients by the iTRAQ-based LC–MS approach. J Proteome Res 14:2466–2479. https://doi.org/10.1021/pr501324n
Ma F, Rodriguez S, Buxo X et al (2016) Plasma matrix metalloproteinases in patients with Stroke during intensive rehabilitation therapy. Arch Phys Med Rehabil 97:1832–1840. https://doi.org/10.1016/j.apmr.2016.06.007
Zhong C, Bu X, Xu T et al (2018) Serum matrix metalloproteinase-9 and cognitive impairment after acute ischemic stroke. J Am Heart Assoc 7:e007776. https://doi.org/10.1161/JAHA.117.007776
Ruiz-Vega G, García-Robaina A, Ismail MB et al (2018) Detection of plasma MMP-9 within minutes. Unveiling some of the clues to develop fast and simple electrochemical magneto-immunosensors. Biosens Bioelectron 115:45–52. https://doi.org/10.1016/j.bios.2018.05.020
Cappellari M, Turcato G, Forlivesi S et al (2018) STARTING-SICH nomogram to predict symptomatic intracerebral hemorrhage after intravenous thrombolysis for stroke. Stroke 49:397–404. https://doi.org/10.1161/STROKEAHA.117.018427
Acknowledgements
L. R. holds a predoctoral fellowship (IFI17/00012), A. B. is supported by the Juan Rodes program (JR16/00008), and A. R. and M. H.-G. are supported by the Miguel Servet program (CPII15/00003 and CPII17/00010, respectively), all from the Instituto de Salud Carlos III. This research has been funded with the research Grants PI16/00981, PI15/00354 and RETICS INVICTUS RD16/0019/0021 from the Instituto de Salud Carlos III, Spain, co-financed by the European Regional Development Fund and SGR 2017/1427 from the Generalitat de Catalunya (AGAUR).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Montaner, J., Ramiro, L., Simats, A. et al. Matrix metalloproteinases and ADAMs in stroke. Cell. Mol. Life Sci. 76, 3117–3140 (2019). https://doi.org/10.1007/s00018-019-03175-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-019-03175-5